Nathan Pennell, MD, PhD
Basic profileAssociate Professor of Medicine, Cleveland Clinic; Senior Vice President, Worldwide Head of Medical Affairs, Hematology & Oncology, Bristol Myers Squibb · Cleveland Clinic
Nathan Pennell is Associate Professor of Medicine, Cleveland Clinic; Senior Vice President, Worldwide Head of Medical Affairs, Hematology & Oncology, Bristol Myers Squibb at Cleveland Clinic. OpenAlex indexes 424 publications with 68,849 citations (h-index 85); ClinicalTrials.gov lists 9 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 1% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Updated 20 Oct 2026
Nathan Pennell, MD PHD, is Associate Professor of Medicine, Cleveland Clinic at Cleveland Clinic Taussig Cancer Institute. The public record shows 424 publications with 69,047 citations (h-index 85), centered on Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Cancer Genomics and Diagnostics. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 15 companies.
- Most recent indexed publication: 2026 · JCO oncology practice
- Top research focus: Lung Cancer Treatments and Mutations
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 15 companies
Generated from the cited public record · current as of 20 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 183.
Clinical & industry
trials, payments and federal fundingPublic positions
sourced statements on record- Senior Vice President
Worldwide Head of Medical Affairs, Hematology & Oncology, Bristol Myers Squibb
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →roi-nj.com ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9500 Euclid Ave
Cleveland, OH 44195-0001
Telephone
216-444-2200Registry record last updated 21 Oct 2011 · collected 28 Jul 2026.
Clinical trials
Updated 20 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites
Sponsor: Case Comprehensive Cancer Center
- Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC
Sponsor: Nathan Pennell, MD, PhD
Industry payments
Updated 20 Oct 2026
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20251 payment
- Takeda Pharmaceuticals U.S.A., Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
24.9%Serotonin-3 Receptor Antagonist12.3%Ondansetron Hcl100%Part D≥21 patientsPotassium supplement7.4%Potassium Chloride100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
20.7%Kinase inhibitor20.7%Tagrisso66%Alecensa34%Part D<11 patientsBlood & clotting
15.8%Factor Xa inhibitor15.8%Eliquis51%Xarelto49%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Congress activity
Updated 20 Oct 2026
102 congress contributions (2007–2025) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
- Association of radiomic features with disease-free survival following neoadjuvant chemoimmunotherapy in resectable NSCLC.
ASCO Annual Meeting
ASCO2025Co-author - Clinical application of a novel, multidisciplinary pharmacovigilance (PV) clinic in patients (pts) with immune-related adverse events (irAEs).
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 20 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Progressive disability but survival advantage in anti-Hu/ANNA1 paraneoplastic neurological syndromes.
Journal of neurology
Article2026 - Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST.
Journal of clinical oncology
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01The Immune Landscape of CancerArticle5,845 citations2018
- 02Comprehensive molecular profiling of lung adenocarcinomaArticle5,711 citations2014
- 03An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome AnalyticsArticle3,692 citations2018
- 04The repertoire of mutational signatures in human cancerArticle3,478 citations2020
- 05Oncogenic Signaling Pathways in The Cancer Genome AtlasArticle3,177 citations2018
Network
Updated 20 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 20 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
connection.asco.org/magazine/asco-member-news/jco-oncology-practice-podcast-behind-scenes-host-dr-nathan-pennell
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →connection.asco.org ↗ - Other
oncologytube.com/second-line-treatment-of-nsclc-patients-before-immuno-oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncologytube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 20 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancergrace.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancergrace.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗
- Director of Lung Cancer Medical Oncology Program
Cleveland Clinic Taussig Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancergrace.org ↗ - Vice Chair of Clinical Research
Cleveland Clinic Taussig Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - Deputy Editor
JAMA Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jamanetwork.com ↗ - Podcast Editor
Journal of Oncology Practice
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancergrace.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →connection.asco.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncologytube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →connection.asco.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Samir Kapadia, MD
Cleveland Clinic
Mina Chung, MD
Cleveland Clinic
Serpil Erzurum, MD
Cleveland Clinic
Arthur McCullough, MD
Cleveland Clinic
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”